Replies to post #382928 on Amarin Corp Plc (AMRN)

[rosemountbomber]

Would they bash a product they are selling? Wouldn't docs stop prescribing and hence no generics could be filled for a non-existent script.

[BioInvestor3]

At this point I'm much less concerned about the science than Amarin getting traction in EU. I can hardly believe they have virtually no sales to speak of outside of the US market. They would certainly do better with a well funded partner but the asking price may be too high, I just don't know the why (it must be a good reason or may be no BP is interested, I have no idea).

[ralphey]

One could ask why AMRN never included a statin intolerant arm in the original REDUCE IT study? Just another grave oversight - Can EPA compete directly with statins?

EPA gave 25% reduction on top of statins what would have been the risk reduction before statins took the lions share ?

We already know its a statin enhancer but instead we market it as fish oil - the absolute zenith of business buffoonery

When it comes to AMRN bet on buffoonery but I'm not certain it can go much lower, there is a certain amount of value in Canada Europe CHina etc - but knowing the buffoons they may be able to screw that up as well.

NOnetheless I am hesitant to short this stock any longer.

[HDGabor]

This strategy to bring death to Amarin by Mineral Oil controversy is probably paid for by the generics

Are you BB' cousin?